Syed Shah, MD
Pulmonary Disease · Cedar Rapids, IANPI 1780036384
Payments from drug & device makers
What this record shows
This record is dominated by education: $7,145 of the $11,902 with a category attached, or 60.0%. Intuitive Surgical accounts for 69.3% of it on its own, with 25 other manufacturers making up the rest.
Across 79 payments — averaging $150.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$8K
- Inspire Medical Systems, Inc.$2K
- Cook Incorporated$417
- Abbott$327
- United Therapeutics Corporation$181
- GSK$156
- plus $1K from 20 others
What the payments were for
- Travel & lodging$2,57222%
- Food & beverage$2,18618%
- Education$7,14560%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 11 | $8,249 |
| Inspire Medical Systems, Inc. | 10 | $1,567 |
| Cook Incorporated | 3 | $417 |
| Abbott | 2 | $327 |
| United Therapeutics Corporation | 6 | $181 |
| GSK | 8 | $156 |
| Harmony Biosciences LLC | 3 | $141 |
| Boehringer Ingelheim | 6 | $120 |
| Jazz Pharmaceuticals Inc. | 3 | $117 |
| AbbVie | 2 | $90 |
| AstraZeneca | 3 | $78 |
| Bayer | 3 | $67 |
| Insmed, Inc. | 2 | $61 |
| Mylan Specialty L.p. | 2 | $43 |
| Sanofi | 2 | $43 |
| Regeneron Healthcare Solutions, Inc. | 2 | $40 |
| Actelion Pharmaceuticals US, Inc. | 2 | $32 |
| Baxter Healthcare | 1 | $28 |
| Johnson & Johnson | 1 | $24 |
| Astellas Pharma US Inc | 1 | $22 |
| Merck | 1 | $21 |
| Verona Pharma, Inc. | 1 | $20 |
| Amgen | 1 | $18 |
| ERBE USA Inc | 1 | $16 |
| Otsuka America Pharmaceutical, Inc. | 1 | $14 |
| Pinnacle Biologics, Inc | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Da Vinci Surgical System$8,156
- Inspire$1,173
- Blue Rhino$328
- DRAGONFLY OPSTAR$174
- COROFLOW$154
How this compares
$11,902 in reported general payments places this provider in the 85th percentile of 110 pulmonary disease providers in Iowa.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 118 | $90,171 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 29 | $20,984 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 43 | $19,760 |
| Spiriva RespimatTiotropium Bromide | 28 | $19,419 |
| Breo ElliptaFluticasone/Vilanterol | 48 | $18,570 |
| SymbicortBudesonide/Formoterol Fumarate | 36 | $13,535 |
| Incruse ElliptaUmeclidinium Bromide | 28 | $12,152 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 32 | $5,271 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 79 | $1,947 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 12 | $1,770 |
| Azelastine Hcl | 18 | $497 |
| Fluticasone Propionate | 80 | $495 |
| Montelukast Sodium | 25 | $282 |
| Prednisone | 13 | $49 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Incruse Ellipta | $156 | $140,653237 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $78 | $34,51965 claims |
| Boehringer IngelheimSpiriva Respimat | $120 | $19,41928 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 110 pulmonary disease providers in Iowa.
Other pulmonary disease in Cedar Rapids
- Hamad AzamCedar Rapids$9K
- Vijaya GogineniCedar Rapids$5K
- Hafiz HashmiCedar Rapids$4K
- Giovanni Cordoba SolisCedar Rapids$2K
- Brian LindsayCedar Rapids$793
- Bryan KrajicekCouncil Bluffs$470K
- Sumit MukherjeeCouncil Bluffs$264K
- John SouthardCouncil Bluffs$184K
- Dustin McCannWest Des Moines$67K
- Alejandro ComellasIowa City$54K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.